Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis surgery for breast cancer-related lymphoedema. by Khan, AA et al.
Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis 
surgery for breast cancer-related lymphoedema 
 
A. A. Khan
1
, I. Hernan
2
, J. A. Adamthwaite
2
 and K. W. D. Ramsey
2
 
 
1
Institute of Cancer Research and 
2
Department of Plastic and Reconstructive Surgery, Royal 
Marsden Hospital, London, UK 
 
Correspondence to: Mr K. W. D. Ramsey, Department of Plastic Surgery, Royal Marsden 
Hospital, Fulham Road, London SW3 6JJ, UK (e-mail: kelvin.ramsey@rmh.nhs.uk) 
 
 
Background: Breast cancer-related lymphoedema (BCRL) presents a significant healthcare 
burden and adversely affects quality of life of breast cancer survivors. A prospective 
feasibility study was performed on lymphaticovenous anastomosis (LVA) for the treatment 
of BCRL. 
Methods: Patients with BCRL underwent near-infrared spectroscopy with indocyanine 
green lymphatic mapping to identify suitable lymphatic channels for LVA. End-to-end 
anastomoses to subdermal venules were performed and patient recommenced compression 
garment therapy (CGT) after surgery. Volumetric assessment of the affected limb was 
performed at regular intervals using infrared perometry to calculate the excess volume 
reduction. 
Results: Over a 24-month interval, 27 patients with BCRL underwent LVA. The median 
duration of lymphoedema was 3.5 (range 0.5–18) years, and the median number of LVAs 
performed was 3 (range 2–5). Twenty-four of the 27 patients completed 12-month follow-up. 
Patients exhibited three patterns of volumetric response following LVA: sustained response 
(16 patients), transient response (5) or no response (6). Sustained responders showed an 
excess volume reduction of −33 per cent at 12 months, and this correlated positively with the 
number of LVAs performed (r = −0.56, P = 0.034). Six of these 16 sustained responders 
were able to downgrade CGT after surgery, and two patients were CGT-free at 12 months. 
Conclusion: LVA resulted in a sustained volume reduction in selected patients and may 
offset the burden of CGT. Further work is required to identify biomarkers that predict a 
favourable response to LVA surgery. 
 
+A: Introduction 
Improvements in local and systemic therapies for breast cancer have heralded a longer phase 
of breast cancer survivorship for patients; consequently, minimizing the long-term adverse 
effects of cancer therapies is imperative. One such adverse effect is breast cancer-related 
lymphoedema (BCRL) as a result of axillary surgery and/or radiotherapy. The incidence of 
BCRL is reported as approximately 20 per cent at 1 year and as high as 40 per cent at 
10 years after breast cancer treatment
1–4
. The impact, both psychological and physiological, 
on patients is unquestionable
5–7
, and the complications of BCRL (cellulitis, ulceration) may 
require prolonged periods of specialist management. The tenets of lymphoedema 
management include patient education, skin care and control of coexisting medical 
conditions that may worsen swelling. Control of limb volume itself has been achieved 
primarily through the use of compression bandaging
8
, manual lymphatic drainage and 
tailored exercise programmes to reduce limb volume and improve skin condition. 
Traditionally, surgical approaches for the management of lymphoedema have been 
palliative (Homan’s operation, Charles’ procedure9,10 and the use of 
omental/enteromesenteric flaps
11
), and are largely obsolete in modern medical practice. 
Although modern volume reduction techniques, such as circumferential liposuction, have 
shown efficacy in reducing limb volume, patients are still required to maintain compression 
therapy regimens
7,12,13
. Surgical approaches to restore normal lymphatic physiology, such as 
lymphaticovenous anastomosis (LVA)
14,15
 or lymph node transfer (LNT)
16–19
, have gained 
popularity in recent years as they offer the potential to normalize lymphatic flow and, 
therefore, reduce the need for compression therapy. No single procedure has, however, yet 
demonstrated sustainable improvements in limb volume reduction and obviated the need for 
compression hosiery. In addition, these procedures are not risk-free, with reports of 
worsening lymphoedema after surgery in some patients undergoing LVA or LNT
20
, as well 
as the risk of developing lymphoedema as a result of LNT harvest
21,22
. Specifically, although 
the existing body of literature suggests that LVA may offer a volume reduction benefit, the 
true efficacy of LVA has been difficult to evaluate because of discrepancies between 
reported series in patient selection and outcome measurement
14,20
. The recent introduction of 
dynamic imaging using indocyanine green (ICG) and near-infrared spectroscopy (NIRS)
23–26
 
has improved reported outcomes as it permits preoperative evaluation of lymphatic flow 
patterns
23,27
 and thus the identification of patients who may benefit from surgery. In 
summary, the early promise of physiological surgery for lymphoedema has yet to translate 
into the body of evidence required to change standard-of-care and allow clinicians to analyse 
the value of evidence-based interventions in BCRL. 
This paper presents the results of a prospective study of performing LVA for BCRL 
using dynamic imaging as part of a microsurgical lymphoedema service. The findings of this 
pilot study are being used to inform the design of a prospective randomized study to evaluate 
the efficacy of LVA in combination with compression garment therapy (CGT) compared 
with CGT alone. 
+A: Methods 
+B: Preoperative clinical assessment 
All patients underwent dual assessment by the senior author and a lymphoedema therapist 
within a dedicated lymphoedema clinic. A standard pro forma was used to capture 
demographic and clinical data including: duration of lymphoedema, symptom status, 
episodes of cellulitis and previous treatment for lymphoedema. Oncological examination 
(clinical and/or radiological if indicated) was performed in all patients to exclude recurrence-
related lymphoedema. Volumetric evaluation was performed using infrared perometry
28
 
(Fig. 1). Excess volume reduction
29–31
 (EVR) was calculated as a percentage using the 
formula: (postoperative change in limb volume/preoperative difference in volume between 
limbs) × 100; otherwise stated as: 
[(Vaffected limb at time t) − (Vaffected limb at baseline)/(Vaffected limb at baseline − Vcontrol limb at 
baseline)] × 100 
 
Negative values for EVR represent volumetric improvements in the affected limb, whereas 
positive values represent further increases in limb volume. 
+b: Lymphatic mapping 
NIRS using ICG was employed to image, dynamically, the lymphatic drainage of the 
affected and unaffected limb. Under local anaesthetic (1 per cent lidocaine without 
adrenaline (epinephrine)), an intradermal/subdermal injection of 0.1–0.2 ml ICG (25 mg in 
5 ml sterile water) was performed in the second web space of the hand and the ulnar border 
of the hand (Fig. 2). NIRS was performed immediately after injection and at serial time 
points thereafter using a hand-held near-infrared camera (PDE System; Hamamatsu 
Photonics UK, Welwyn Garden City, UK). Functioning lymphatic vessels were identified by 
selecting those displaying appropriate structure and propulsion and marked (Fig. 2c,d). LVA 
was offered only to patients with suitable functional lymphatics on dynamic imaging, in the 
context of compression-refractory lymphoedema. Patients were maintained at their 
preoperative level of compression immediately before surgery and afterwards. 
+B: Technique of lymphaticovenous anastomosis 
Before induction of anaesthesia ICG was injected as described above under local anaesthetic 
block. Under general anaesthetic, lymphatic mapping was performed and suitable lymphatic 
channels were identified and their course marked. Multiple sites for LVA were identified 
along the course of suitable lymphatic channels, and small incisions were made at each LVA 
location. Subdermal venules lying juxtaposed to the identified lymphatic channels were 
identified (Fig. 3) and dissected under magnification (39×, Zeiss OPMI Vario/S88 
microscope with Zeiss foldable tube f170/f260 attachment (Carl Zeiss AG, Oberkochen, 
Germany) using supermicrosurgical instruments (S&T AG, Neuhause, Switzerland). LVA 
was carried out in an end-to-end
32,33
, hand-sewn manner using a 12/0 S&T
®
 suture on a 50-
m needle (Fig. 4 and 5). 
Anastomoses were performed between the proximal lymphatic and distal venule to 
minimize the risk of size discrepancy and with the aim of performing between three and five 
LVAs per limb. Anastomotic patency was demonstrated by visualization of ICG flow across 
the anastomosis. Incisions were closed with non-absorbable sutures and skin glue, and the 
limb dressed with wool and crepe. 
Patients were given intravenous antibiotics at induction of anaesthesia and a 5-day 
course of oral antibiotics after surgery. The limb was elevated for 3 days after surgery using 
a high-arm sling, and a wound check was performed in the clinic at 1 week. Sutures and 
bandages were removed at 2 weeks, and compression therapy was recommenced at the same 
level as before surgery. 
Perometry assessments were performed by lymphoedema therapists at 1, 3, 6 and 
12 months after surgery, and patients were also reviewed by the senior surgeon at these 
times. Perometry assessments were used to guide changes to CGT in combination with 
clinical assessment and discussion with the patient. 
+B: Study design and statistical analysis 
The objective of this study was to evaluate the volume reduction attributable to LVA in 
patients with BCRL. The primary endpoint of the study was limb volume as measured by 
infrared perometry, and the secondary endpoint was grade of compression therapy. The 
intention of this study was to inform the subsequent design of a randomized trial and, 
therefore, a formal sample size calculation was not performed. Institutional review of the 
protocol was undertaken, and approval was gained before commencement. 
Comparison of mean values between groups was performed using Student’s t test 
(unpaired), and one-way ANOVA with Bonferroni post hoc correction) was carried out for 
multiple groups. χ2 contingency analyses were performed to evaluate categorical data. 
Correlations were evaluated using Pearson’s r statistic. Significance was attributed to 
P values of less than 0.050 and all analyses were performed using Graphpad Prism version 7 
(GraphPad Software, La Jolla, California, USA).  
+A: Results 
,Between October 2012 and May 2014, 118 patients were referred to the lymphoedema 
clinic of whom 82 (69 per cent) had BCRL. Of these 82 patients referred for assessment, 27 
(33 per cent) underwent LVA surgery. Of the final cohort, five patients were referred with 
new-onset lymphoedema following axillary dissection (at less than 12 months) and 22 were 
referred with established lymphoedema to assess the feasibility of LVA. Their mean BMI 
was 24.8 (range 20.0–38.4) kg/m2 (Table 1). All patients were non-smokers. The mean 
duration of lymphoedema before LVA surgery was 3.5 (range 0.5–18) years. The mean 
number of LVAs performed was 3 (range 2–5). 
+B: Previous treatments for lymphoedema  
All patients who underwent LVA wore compression garments before surgery (grade 1, 3; 
grade 2, 21; grade 3, 3). Twenty-two of the 27 patients were receiving ongoing manual 
lymphatic drainage, and 11 had undergone intensive treatment with multilayer bandaging at 
some time (Table 1). 
+B: Previous breast cancer treatment  
Eleven of the 27 patients with BCRL had undergone breast-conserving surgery (BCS) as part 
of their breast cancer treatment, and the other 16 had had a mastectomy. Twelve patients had 
undergone immediate autologous reconstruction (free transverse rectus abdominis 
myocutaneous flap, deep inferior epigastric artery perforator flap, or latissimus dorsi flap 
with implant) at the time of mastectomy. All 27 patients had undergone axillary node 
dissection with a mean of 2 (range 0–24) positive nodes of a mean harvest of 17 (range 10–
27) axillary nodes. Twenty-five patients had received radiotherapy (chest wall, 
supraclavicular fossa or internal mammary chain), and two had an axillary boost. Twenty-six 
patients had received either neoadjuvant or adjuvant chemotherapy, and 19 were being 
treated with hormonal therapy (Table 1). 
+B: Lymphaticovenous anastomosis 
All patients were operated on under general anaesthesia as planned day-case procedures. The 
mean duration of surgery was 3.3 (s.d.=0.45) h. Patients were recovered in a ward 
environment for 6 h after surgery before discharge later the same day. 
+B: Volumetric outcomes 
Twenty-four of the 27 patients who underwent LVA were followed up for 12 months after 
surgery. 
The mean(s.e.m.) EVR across all patients was −14.0(8.0) per cent at 1 month, 
2.9(13.7) per cent at 3 months, −0.6(9.9) per cent at 6 months and 9.2(14.7) per cent at 
12 months. 
Subgroup analysis of the overall cohort found three different patterns of response: 
sustained responders (16 patients), transient responders (5) and non-responders (6) (figures 
7A-C). Sustained responders exhibited significantly greater mean (s.d.) EVR compared with 
non-responders at all time points (P=0.014), and compared with transient responders at 
12 months only (−33.2(34.9) versus 102.0(75.8) per cent respectively; P=0.002) (figures 6 
and 8 and Table 2). Transient responders showed early volumetric improvements (at 1 and 
3 months) before relapsing. Of particular note, two of the five patients who had a transient 
response developed postoperative cellulitis. Both episodes were delayed in onset (4 and 
9 months after LVA), and in one patient was secondary to a thumb laceration. All six non-
responders had a mean increase in excess volume of 51.5 (range 31.4–75.5) per cent at 
12 months. 
Correlation analyses of sustained responders demonstrated that, at 12 months, greater 
EVR was significantly associated with the number of LVAs performed (r = −0.56, 
P = 0.034) (figure 9). 
To identify factors that might predict a poor outcome (transient or no response) 
following LVA, multiple variables were analysed to investigate how these differed between 
response subgroups. Transient responders had a significantly greater duration of 
lymphoedema before LVA surgery (adjusted P = 0.044), but non-responders did not. No 
significant associations were observed between LVA response and BMI (P = 0.748), number 
of positive nodes harvested (P = 0.458), total number of axillary nodes harvested 
(P = 0.790), axillary radiotherapy (P = 0.519), hormonal therapy (P = 0.683) or previous 
autologous reconstruction (P = 0.152), or type of previous breast surgery (BCS or 
mastectomy) (P = 0.157) (Table 3). 
The preoperative distribution of CGT grades in sustained responders was: grade 1, one 
patient; grade 2, 13 patients; and grade 3, two patients. Following LVA, there were five, 11 
and zero patients receiving grade 1, 2 and 3 compression therapy. Contingency analysis 
demonstrated that these proportions were significantly different (P =0.045) (figure 10). Six 
of the 16 sustained responders had downgraded CGT after surgery, and two patients in the 
overall cohort ceased to require compression altogether. The decision to downgrade CGT 
was made jointly with the patient following clinical and perometry assessment of the 
affected limb after surgery. No patient who had a reduction in CGT grade experienced 
rebound swelling of the limb. 
With a view to designing a prospective randomized trial, a further subgroup analysis of 
patients who might be eligible for such a study was performed. In our protocol, we propose 
to recruit patients prospectively following axillary clearance and, to this end, we sought to 
investigate whether the duration of lymphoedema might affect volumetric outcomes post-
LVA. EVR was compared in patients with a duration of lymphoedema of less than 2 years 
and those with a duration of greater than 2 years: mean(s.d.) EVR −26.1(50.2) versus 
16.5(39.6) per cent respectively (P = 0.041) (figure 11). 
+A: Discussion 
BCRL commits patients to a lifelong regimen of CGT and increases the risk of 
complications such as cellulitis, lymphangitis, lymphadenitis and ulceration. It can impair 
quality of life significantly
34,35
, have a profound psychological impact, and be a reminder of 
cancer diagnosis. In rare instances, it can predispose to developing lymphangiosarcoma
36
 
and retiform lymphangioendothelioma
37
. Although physiological lymphatic surgery such as 
LVA may offer a therapeutic benefit, the impetus is on the surgeon to select only those 
patients who may benefit and, above all, avoid interventions that may worsen BCRL. 
Surgical strategies for BCRL have traditionally been associated with poor outcomes 
and high complication rates. Excisional procedures such as Homans’ operation and the 
Charles procedure, which are now largely obsolete, had disastrous cosmetic results and a 
questionable impact on lymphoedema. Similarly, omental and enteromesenteric flaps
11
 were 
used as a way of bridging damaged lymphatics, but were associated with poor volumetric 
outcomes and unacceptable complication profiles. Liposuction, which is effective in 
reducing limb volume, does not address the underlying disease process and is limited to 
patients in whom there is a significant adipose component. It does not obviate the need for 
ongoing CGT, and concern remains over liposuction worsening the fibrotic component of 
lymphoedema
7,12,13
. Although LNT may offer the possibility of anatomical lymphatic 
reconstruction, evaluating its true efficacy is difficult and donor site morbidity remains a 
concern
22,39,40
; however, a comprehensive discussion of its value is beyond the remit of the 
present study. Recent preclinical reports
41,42
 of LNT in combination with vascular 
endothelial growth factor C gene therapy are encouraging, and clinical trial data from 
translation of this strategy are awaited. Preclinical efficacy for leukotriene antagonists has 
been reported recently
43
, and these are currently being evaluated in a phase 2 clinical trial. 
LVA offers the opportunity for lymphatic reconstruction with relatively less morbidity 
and, although LVA has been introduced cautiously into routine clinical practice in the UK, it 
is now offered in several UK centres. We present the first UK series of LVA in combination 
with NIRS imaging for BCRL in the UK, with data collected from a clinical LVA service. It 
is the experience of the present authors that setting up a lymphoedema surgery service 
requires significant investment in infrastructure, equipment and, perhaps most importantly, 
capacity and training for specialist lymphoedema therapists. Such expenditure has to be 
justifiable with regard to outcome, and thus the focus has been on standardizing the 
processes using validated methods of assessment and treatment to ensure robust and reliable 
outcome data. Specifically, the postoperative compression regimen employs the same degree 
of compression as was used before surgery. Adoption of the International Society of 
Lymphology consensus document
44
 to enable standardization of data collection is advocated 
for evaluation of all therapeutic interventions for lymphoedema. 
In the present series, one-third of patients referred with BCRL were identified as 
suitable candidates for LVA on the basis of clinical evaluation in combination with 
favourable NIRS imaging using ICG. The patient population was highly heterogeneous with 
regard to breast cancer treatment, breast reconstruction, duration of lymphoedema (range 
0.5–18 years) and previous treatments for lymphoedema. A mean number of three LVAs 
were performed per affected limb, and patients recommenced CGT 2 weeks after surgery at 
the same level as before the operation. 
Twenty-four of the 27 patients achieved 12-month follow-up. No response to LVA 
was observed in six patients, whereas a transient response was achieved in five and a 
sustained volume reduction in 16. Sustained responders had a 33 per cent reduction in excess 
volume at 12 months, which was correlated with the number of LVA procedures performed 
and associated with a downgrading of CGT in six of the 16 patients in this group. Transient 
responders exhibited early volumetric improvements following LVA, but ultimately 
relapsed; of note, two of these five patients had postoperative cellulitis. It is likely that 
infection adversely affected the LVA, although there are few published data on the impact of 
postoperative cellulitis on the efficacy of LVA. Although it is not possible to demonstrate 
causality between infection and adverse volumetric outcomes after LVA, recent evidence
45
 
suggests that methicillin-resistant Staphylococcus aureus infection results in lymphatic 
muscle dysfunction that persists long after the infection has been cleared. 
In the present study, a mean 51.5 per cent increase in excess volume was observed in 
non-responders at 12 months. Other published series have reported no change, or a 
deterioration, in lymphoedema in up to 40 per cent of patients treated with LVA
46
, compared 
with the 22 per cent (6 of 27) non-response rate in the present series. Although the numbers 
in the no-response group are too small to demonstrate causality between non-response to 
LVA and worsening limb volume, further data are required to differentiate between 
increases in limb volume attributable to LVA failure and the natural evolution of volume 
changes in lymphoedema. It is likely that this might be shown only in suitably powered 
studies with large control arms of similar patients. The present analysis showed that longer 
duration of lymphoedema before LVA was associated with worse volume outcomes, but no 
associations were observed between volume and breast cancer treatment variables, including 
axillary radiotherapy and the number of axillary nodes removed. 
This feasibility study has highlighted the natural learning curve involved in 
introducing a LVA service. Performing LVA under general anaesthetic is advocated both for 
patient comfort and to ensure that the anastomosis is not jeopardized by movement. Ideally, 
surgery should be performed by surgeons operating in parallel, which would allow for a 
greater number of LVAs per patient and reduce operating time. The optimal number of 
LVAs to perform per limb remains debated. In a previous study
15
, three LVAs per limb were 
performed, and in the present study patients with greater volume reductions had a higher 
number of LVAs. However, identification of these patients a priori is currently not possible. 
The timing of intervention with LVA remains much debated, but the available 
literature supports earlier intervention, before the development of adipose tissue proliferation 
or fibrotic change. The present comparison of volumetric outcomes in patients with long-
standing lymphoedema (more than 2 years) with those in patients with a shorter duration 
(less than 2 years) suggested that earlier intervention was associated with significant 
improvements in EVR following LVA. Newer approaches advocate for immediate LVA at 
the time of axillary dissection
47,48
, although the benefit of this remains to be established, as 
only a proportion of patients undergoing axillary dissection will ultimately develop 
lymphoedema. 
Data from this series have been used to inform the design of a prospective randomized 
trial of LVA with CGT versus CGT alone in patients with BCRL (Fig. S1, supporting 
information). That study will aim to randomize patients to LVA early after the diagnosis of 
BCRL and evaluate the impact LVA in this group. The study protocol for the randomized 
study aims to follow all patients having axillary dissection and recruit patients who exhibit 
persistent limb swelling (duration longer than 1 month). Identifying patients who may not 
benefit from LVA is paramount, and the authors hypothesize that relevant biomarkers may 
aid in the stratification of patients and facilitate the prospective identification of LVA non-
responders. The future trial platform will allow formal evaluation of a panel of biomarkers 
against volumetric outcomes. 
This first UK series of LVA for BCRL demonstrates that the procedure may offer a 
volume reduction benefit in some patients; however, prospective identification of these 
patients remains difficult. The surgery itself was associated with relatively low morbidity, 
but postoperative infections may compromise the efficacy of LVA and worsen 
lymphoedema. The efficacy of LVA in BCRL will be analysed within the framework of a 
prospective randomized trial. 
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<TYPESETTER: PLEASE FOLLOW MARK-UPS OF FIGS 1-11> 
 
Fig. 1 Infrared perometry limb volume measurement being performed by a lymphoedema therapist 
 
Fig. 2 a Injection of indocyanine green (ICG) (0.1 ml of 5-mg/ml solution) into the left hand (normal limb) 
under local anaesthetic. Injections are typically performed in the second web space and along the ulnar border. 
b Near-infrared spectroscopy (NIRS) immediately after injection of ICG, demonstrating early uptake along 
lymphatic channels. c Surface markings demonstrate the course of the basilic vein (arrow). d NIRS view of 
basilic vein (black arrow) with prominent uptake into adjacent lymphatic channels (white arrows), confirming 
feasibility of lymphaticovenous anastomosis (LVA). e Dermal backflow ‘stardust’ appearance of lymphatic 
flow caused by reflux of ICG into dermal lymphatics, and an absence of linear lymphatic channels suggesting 
that LVA will not be feasible due to lymphoedema progression 
 
Fig. 3 Intraoperative photograph of lymphatic channel (L) (containing indocyanine green) dissection and 
adjacent venule (V) 
 
Fig. 4 Microsurgical setup for anastomosis, demonstrating proximity of lymphatic channel (L) and venule (V) 
to facilitate tension-free anastomosis 
 
Fig. 5 a Photograph of a completed lymphaticovenous anastomosis (LVA) at the time of removal of distal 
microvascular clamps. b Demonstration of LVA patency as shown by indocyanine green flow into the distal 
limb of the LVA 
 
Fig. 6 a Preoperative photograph of a patient with left-sided upper limb lymphoedema; b postoperative 
photograph of the same patient 12 months after lymphaticovenous anastomosis  
 
Fig. 7 Changes in excess volume reduction (EVR) at 1, 3, 6 and 12 months after lymphaticovenous 
anastomosis (LVA) in a sustained responders, b transient responders and c non-responders. Values are 
mean(s.d.) 
  
 
 
Fig. 8 Comparison of excess volume reduction (EVR) in sustained responders (SR), transient responders (TR) 
and non-responders (NR) at 12 months after lymphaticovenous anastomosis. Values are mean(s.d.). *P < 0.050, 
†P < 0.010 (one-way ANOVA) 
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Fig. 9 Correlation between mean excess volume reduction (EVR) at 12 months in sustained responders and the 
number of lymphaticovenous anastomoses (LVAs) performed. Pearson’s r = −0.56, P = 0.034 
 
Fig. 10 Compression garment therapy (CGT) grade in sustained responders before and after lymphaticovenous 
anastomosis (LVA). *P =0.045 (χ2 contingency analysis) 
 
 
 
Fig. 11 Comparison of excess volume reduction (EVR) in sustained responders with duration of lymphoedema 
from diagnosis of less than 2 years and those with duration greater than 2 years. Values are mean(s.d.). 
P < 0.050 (Student’s unpaired t test)  
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Table 1 Demographics, previous breast cancer treatment and previous treatments for lymphoedema 
 No. of patients* (n = 27) 
Duration of lymphoedema (years)† 3.5 (0.5–18) 
BMI (kg/m
2
)† 24.8 (20.0–38.4) 
Smoker 0 
Diabetes mellitus 0 
Previous breast cancer treatment  
Breast-conserving surgery 11 
Mastectomy 16 
Immediate autologous reconstruction‡ before 
development of lymphoedema 
12 
Axillary node dissection 27 
No. of positive nodes† 2 (0–24) 
No. of harvested nodes† 17 (10–27) 
Radiotherapy  
Any (breast, SCF, axilla) 25 
Axilla 2 
Any chemotherapy (neoadjuvant or adjuvant) 26 
Hormonal therapy 19 
Previous lymphoedema treatment  
Compression therapy  
Grade 1 3 
Grade 2 21 
Grade 3 3 
Manual lymphatic drainage 22 
Intensive treatment with wrapping 11 
*Unless indicated otherwise; †values are mean (range). ‡Muscle-sparing transverse rectus abdominis 
myocutaneous, deep inferior epigastric artery perforator, or latimssimus dorsi plus implant flaps. SCF, 
supraclavicular fossa. 
 
  
Table 2 Volumetric outcomes as measured by perometry across subgroups 
 Excess volume reduction (%) 
Sustained response Transient response No response 
Time after LVA (months)    
1 −30.8(8.1) −12.3(12.3) 37.9(14.9) 
3 −23.2(11.1) 28.4(52.4) 55.3(56.7) 
6 −20.4(7.9) 19.5(32.2) 53.4(13.3) 
12 −33.2(9.0) 102.0(33.9) 52.3(10.7) 
Values are mean(s.e.m.). LVA, lymphaticovenous anastomosis. 
 
  
Table 3 Analysis of potential clinicopathological variables affecting volumetric outcomes following 
lymphaticovenous anastomosis 
 Sustained response 
(n = 16) 
Transient 
response (n = 5) 
No response 
(n = 6) 
P† 
Duration of lymphoedema (years)* 2.8 (0.5–8) 7.5* (1.1–18) 4.4 (1–7) 0.047‡ 
No. of LVAs* 3.0 (2.0–4.0) 3.6 (2.0–5.0) 3.0 (2.0–5.0) 0.409‡ 
BMI (kg/m
2
)* 26.2 (20.0–38.1) 27.6 (23.2–33.2) 25.8 (21.6–34.2) 0.748‡ 
Previous BCS 8 2 1 0.241 
Previous mastectomy 8 3 5 0.241 
No. of positive nodes* 6.0 (0–24) 2.0 (0–6) 1.7 (0–3) 0.458‡ 
No. of nodes harvested* 17.2 (7–27) 17.5 (13–22) 20.0 (15–25) 0.790‡ 
Any radiotherapy 15 5 5 0.617 
Radiotherapy to axilla 2 0 0 0.519 
Hormonal therapy 11 3 5 0.683 
Previous autologous reconstruction 5 4 3 0.152 
*Values are mean (range). LVA, lymphaticovenous anastomosis; BCS, breast-conserving surgery. †χ2 
contingency analysis, except one-way ANOVA. 
 
 
 
 
